Literature DB >> 22902724

Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway.

Elizabeth A Miller1, Meredith R Spadaccia, Meagan P OʼBrien, Linda Rolnitzky, Rachel Sabado, Olivier Manches, Davor Frleta, Nina Bhardwaj.   

Abstract

OBJECTIVE: Myeloid dendritic cell (mDC) dysfunction during HIV infection may hinder the formation of both innate and adaptive immune responses and contribute to pathogenesis. Our objective was to determine whether circulating factors during chronic HIV infection impair mDC function with respect to secretion of IL-12, a pro-Th1 cytokine, and T-cell stimulatory capacity. Particular focus was placed on the effect of combination antiretroviral therapy (cART) and the role of HIV itself on mDC function.
METHODS: Monocyte-derived DC (moDC) from uninfected donors were exposed to plasma from HIV-infected individuals before Toll-like receptor (TLR) stimulation. Cytokine secretion was measured via cytokine bead arrays, and T-cell proliferation and IFNγ secretion was evaluated after coculture with naive CD4 T cells. Expression of genes central to TLR-mediated signal transduction was analyzed via quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) arrays and western blot.
RESULTS: Exposure of monocyte-derived DC to plasma from untreated HIV-infected donors suppressed secretion of IL-12, and impaired Th1-skewing of CD4 T cells. The suppressive effect was less by plasma donors receiving cART. Removal of virus from plasma did not relieve suppression nor was IL-12 secretion decreased on addition of HIV to control plasma. On a transcriptional level, decreased expression of IKKβ, a key regulator in the TLR/NF-kappaB signaling pathway, corresponded to suppressed cytokine secretion.
CONCLUSIONS: Plasma factors during chronic HIV infection impair mDC function in a manner that likely impacts the formation of immune responses to HIV, opportunistic pathogens, and vaccines. Despite partial alleviation by cART, this suppression was not directly mediated by HIV.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902724      PMCID: PMC3508089          DOI: 10.1097/QAI.0b013e31826afbce

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  57 in total

1.  HIV-associated dysfunction of in vitro IL-12 production depends on the nature of the stimulus and on the CD4 T-cell count of the patient.

Authors:  G Vanham; L Penne; K Fransen; L Kestens; M De Brabander
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

2.  Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12.

Authors:  Redouane Rouas; Philippe Lewalle; Frank El Ouriaghli; Berengere Nowak; Hughes Duvillier; Philippe Martiat
Journal:  Int Immunol       Date:  2004-03-29       Impact factor: 4.823

3.  In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS.

Authors:  F Villinger; S Bucur; N F Chikkala; S S Brar; P Bostik; A E Mayne; J Adams; M E Lee; F J Novembre; M K Gately; A A Ansari; C D Hillyer
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

4.  CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness.

Authors:  M Dybul; G Mercier; M Belson; C W Hallahan; S Liu; C Perry; B Herpin; L Ehler; R T Davey; J A Metcalf; J M Mican; R A Seder; A S Fauci
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

5.  Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques.

Authors:  A A Ansari; A E Mayne; J B Sundstrom; P Bostik; B Grimm; J D Altman; F Villinger
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection.

Authors:  Richard T Lester; Xiao-Dan Yao; T Blake Ball; Lyle R McKinnon; Rupert Kaul; Charles Wachihi; Walter Jaoko; Francis A Plummer; Kenneth L Rosenthal
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

7.  HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection.

Authors:  Marco Mirani; Ilia Elenkov; Simona Volpi; Naoki Hiroi; George P Chrousos; Tomoshige Kino
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

8.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Authors:  Peter W Hunt; Jason Brenchley; Elizabeth Sinclair; Joseph M McCune; Michelle Roland; Kimberly Page-Shafer; Priscilla Hsue; Brinda Emu; Melissa Krone; Harry Lampiris; Daniel Douek; Jeffrey N Martin; Steven G Deeks
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

9.  The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.

Authors:  Christine Trumpfheller; Marina Caskey; Godwin Nchinda; Maria Paula Longhi; Olga Mizenina; Yaoxing Huang; Sarah J Schlesinger; Marco Colonna; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

10.  HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.

Authors:  Meimei Shan; Per Johan Klasse; Kaustuv Banerjee; Antu K Dey; Sai Prasad N Iyer; Robert Dionisio; Dustin Charles; Lila Campbell-Gardener; William C Olson; Rogier W Sanders; John P Moore
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

View more
  20 in total

1.  Macrophages and Myeloid Dendritic Cells Lose T Cell-Stimulating Function in Simian Immunodeficiency Virus Infection Associated with Diminished IL-12 and IFN-α Production.

Authors:  Elizabeth R Wonderlich; Wen-Chi Wu; Daniel P Normolle; Simon M Barratt-Boyes
Journal:  J Immunol       Date:  2015-08-21       Impact factor: 5.422

Review 2.  Advances in dendritic cell immunotherapies for HIV-1 infection.

Authors:  Elizabeth Miller; Nina Bhardwaj
Journal:  Expert Opin Biol Ther       Date:  2014-08-21       Impact factor: 4.388

Review 3.  HIV infection: focus on the innate immune cells.

Authors:  Milena S Espíndola; Luana S Soares; Leonardo J Galvão-Lima; Fabiana A Zambuzi; Maira C Cacemiro; Verônica S Brauer; Fabiani G Frantz
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

Review 4.  Residual immune dysregulation syndrome in treated HIV infection.

Authors:  Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

5.  Differential partial activation phenotype and production of tumour necrosis factor-α by conventional dendritic cells in response to lipopolysaccharide in HIV+ viraemic subjects and HIV+ controllers.

Authors:  R Camacho-Sandoval; P M Del Río Estrada; A Rivero-Arrieta; G Reyes-Terán; L C Bonifaz
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

6.  Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.

Authors:  Elizabeth Miller; Meredith Spadaccia; Rachel Sabado; Elena Chertova; Julian Bess; Charles Mac Trubey; Rose Marie Holman; Andres Salazar; Jeffrey Lifson; Nina Bhardwaj
Journal:  Vaccine       Date:  2014-11-15       Impact factor: 3.641

7.  Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.

Authors:  Elizabeth A Miller; Meredith R Spadaccia; Thomas Norton; Morgan Demmler; Ramya Gopal; Meagan O'Brien; Nathaniel Landau; Thomas W Dubensky; Peter Lauer; Dirk G Brockstedt; Nina Bhardwaj
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 8.  Aging of the human innate immune system in HIV infection.

Authors:  Heidi J Zapata; Albert C Shaw
Journal:  Curr Opin Immunol       Date:  2014-07-02       Impact factor: 7.486

Review 9.  Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Authors:  Nichole R Klatt; Nicolas Chomont; Daniel C Douek; Steven G Deeks
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 10.  Dendritic cell dysregulation during HIV-1 infection.

Authors:  Elizabeth Miller; Nina Bhardwaj
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.